Update on Appropriate Use Criteria for Amyloid PET Imaging: Dementia Experts, Mild Cognitive Impairment, and Education
Year: 2013
Type: article
Abstract: Amyloid PET imaging is a novel diagnostic test that can detect in living humans one of the two defining pathologic lesions of Alzheimer disease, amyloid-β deposition in the brain. The Amyloid Imaging Task Force of the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging previously published appropriate use criteria for amyloid PET as an important tool for increasing the certainty of a diagnosis of Alzheimer disease in specific patient populations. Here, the task force further clarifies and expands 3 topics discussed in the original paper: first, defining dementia experts and their use of proper documentation to demonstrate the medical necessity of an amyloid PET scan; second, identifying a specific subset of individuals with mild cognitive impairment for whom an amyloid PET scan is appropriate; and finally, developing educational programs to increase awareness of the amyloid PET appropriate use criteria and providing instructions on how this test should be used in the clinical decision-making process.
Source: Journal of Nuclear Medicine
Institutions: Harvard University, Massachusetts General Hospital, University of Washington, University of Michigan, VA Ann Arbor Healthcare System, Michigan Medicine, Ann Arbor VA Medical Center, Beth Israel Deaconess Medical Center, University of Utah, National Institutes of Health, National Institutes of Health Clinical Center, University of Pennsylvania, The University of Melbourne, Austin Hospital, Austin Health, Society of Nuclear Medicine and Molecular Imaging, Alzheimer's Association
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2097567144